What does GRI Bio, Inc. do?

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T…

What is GRI Bio, Inc.'s P/E and P/B ratio?

GRI Bio, Inc. has a P/E ratio of -0.1 and a P/B ratio of 0.30.

What is GRI Bio, Inc.'s debt-to-equity ratio?

GRI Bio, Inc. has a debt-to-equity ratio of 0.00.

How much does GRI Bio, Inc. owe compared with what it owns?

GRI Bio, Inc. owes $0.10 for every $1 it owns (balance sheet Jun 2026), which is low.

Does GRI Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Yes. GRI Bio, Inc. has 2 active red flags (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 16 Jan 2026); Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 02 Dec 2025). It has no yellow flags.

Where can I read the latest news about GRI Bio, Inc.?

Recent headlines about GRI Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does GRI Bio, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of GRI Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

GRI Bio, Inc.

Q: What is GRI Bio, Inc.'s Positivity rank?

GRI Bio, Inc. is ranked #2,061 of 6,774 companies globally and #564 of 4,000 in United States on PositoAI, with a Positivity Score of 21,949.

NasdaqCM: GRI · Healthcare

Positivity Index

#2,061 / 6,774

Global

#564 / 4,000

United States

Positivity Score

21,949

Rank→

PosiRed: 2 active red flags (highest severity 6/10) View flag history →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 02 Dec 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

GRI Bio, Inc. — Overview & Financial Snapshot

GRI Bio, Inc. (NasdaqCM: GRI) is a Healthcare company, ranked #2,061 of 6,774 companies globally and #564 of 4,000 in United States on PositoAI, with a Positivity Score of 21,949. Its market capitalisation is ₹29.30 Cr ($3.10M), P/E ratio is -0.1 and P/B ratio is 0.30. It currently has 2 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →